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“…We apparently appear to have in front of  
us a peculiar disease process… 
we should not let ourselves to be satisfied 
 with trying to include (…) 
any clinically unclear illness case into one  
of the diagnostic entities known to us” 
-Alois Alzheimer- 
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Introduction 
A. Alzheimer’s Disease. 
I. Alzheimer’s disease pathology: An overview 
 
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder leading to dementia 
discovered in early 900’. In fact, the clinical evaluation of an “unusual case of psychiatric illness” 
described by Dr. Alois Alzheimer, was reported for the first time in 1906, and this case-report gave 
the basis for centuries of research aiming to elucidate mechanisms causing the disease and 
approaches for discovering effective cures [1]. 
Dr. Alois Alzheimer and Dr. Gateano Perusini gave a pivotal contribute to the first histological 
characterization of the disease, with the drawings of post mortem lesions observed in their patient, 
in an era where the electron microscopy was not invented yet. Particularly, they found that 
hallmarks of the disease were neurofibrillary tangles and amyloid plaques. However, these disease 
hallmarks described for the first time in Alzheimer’s laboratory were confirmed only 60 years later, 
together with the correlation between AD lesions and cognitive decline and the acceptance that AD 
was a common pathology of the elderly [2]. Despite the similarity of hallmarks, there are different 
forms of Alzheimer’s disease, that can be divided into two categories that will be described in detail 
in the following chapter. 
Histopathologically as AD progresses, it is possible to observe a massive cortex degeneration, 
particularly affecting the limbic regions and the subcortical nuclei. Together with cortical 
degeneration, it is also possible to observe an increase of ventricles diameter and a functional 
alteration of limbic and para-limbic structures, an alteration of Wernicke’s and Broca’s area and 
the disruption of the parietal-frontal network, thus resulting in the manifestation of the typical 
symptomatology characterized by: amnesia, aphasia, agnosia, apathy, language alteration, loss of 
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spatial orientation and executive dysfunction. These macroscopic alterations are combined with 
microscopic lesions, referred as amyloid plaques and neurofibrillary tangles, along with synaptic 
dysfunction. Amyloid plaques are large proteinaceous precipitates largely composed by amyloid 
beta peptides (Ab), the cleavage product of the Amyloid precursor protein (APP). Neurofibrillary 
tangles are large intracellular aggregates formed by the accumulation of tau protein, a microtubule 
binding protein, due to hyper-phosphorylation of this protein, mainly in pyramidal neurons. 
However, neurofibrillary tangles are not an exclusive lesion of AD, as these lesions are 
characteristic also of other pathologies [3]. 
All lesions observed in post mortem AD brains are the result of decades long disease 
progression, and these lesions correlate only partially with the onset of the disease. [4-7]. Moreover, 
symptoms that can be diagnoses are the outcome of a very slow progression of the disease, that 
might take up to decades before it is possible to clearly diagnose the disease. In fact, as described 
in figure 1, initial biomarkers of AD start their manifestation several decades before the disease can 
be clearly diagnosed as a dementia. Particularly, the very first alteration linked to the disease is the 
accumulation of amyloid beta in the cerebral spinal fluid (CSF Ab42, black cure, figure 1) during 
a pre-symptomatic stage of the disease and therefore almost impossible to diagnose. Subsequently, 
it is possible to detect other biomarkers of the disease, like amyloid deposition and hyper- 
phosphorylated tau protein.       
 
 
Figure 1. AD progression and biomarkers onset. [8]. 
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Based on the “DSM-IV Criteria” used in clinics to assess psychiatric disorders, to be classified 
as “Alzheimer’s disease” there should be a clear impairment of short term memory and at least one 
of the following symptoms: aphasia, apraxia, agnosia, executive dysfunction, and these lesions are 
not related to any other medical condition. Additionally, it is also taken into consideration the 
possible presence of one of the genetic mutations known to correlate with the disease (APP, PSEN1, 
PSEN2 are the genes involved) [9]. 
One important characteristic of AD pathology is the degree of complexity characterizing both 
the onset of the disease and its progression. Moreover, the increased knowledge of some of the 
biomolecular mechanisms leading to AD pathology, led to several controversies and to the 
reevaluation of several aspects of the disease. Noteworthy, the discovery of a cohort of individuals: 
“Non-Demented with Alzheimer’s Neuropathology” (NDAN). In fact, these individuals, even 
though they are histopathological undistinguishable from AD patients, due to the presence of 
amyloid plaques and neurofibrillary tangles, their cognitive abilities are completely different, based 
on the cognitive tests administrated to both groups. One possible explanation to this phenomenon 
is that, even though levels in Ab1-42 are increased in both groups, the binding of Ab to post synaptic 
termini in NDAN is dramatically decreased compared to AD individuals, and therefore NDAN are 
cognitively intact. [10-15]. This important discovery suggests that there are certain mechanisms of 
resistance that protects against the biomolecular alterations responsible for the disease and that 
effectively protects NDAN individuals against AD pathology. Hence, this evidence supports the 
complexity of AD pathology, and suggests the existence of complex pathways governing the 
progression of the disease [10, 16]. However, despite decades of research, there are no effective 
therapies available for reversing AD symptoms [17,18]. Possible reasons for the absence of “disease 
modifying therapies” are the complexity of factors leading to the onset of the disease, and the high 
comorbidity with other disorders [19]. Among all factors causing the disease, one of the earliest 
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hallmarks of AD pathology is amyloid beta peptide (Ab) formation from amyloid precursor protein 
(APP) cleavage, a cascade operated by beta and gamma secretases [7, 20, 21]. As will be described 
in detail in a dedicated section, upon APP cleavage, Ab is released and aggregates into toxic 
oligomers responsible for triggering AD pathogenesis. Nevertheless, the etiology of AD is far more 
complex and it cannot be excluded that the onset of the disease is triggered by a highly complex 
network of several factors, including aging, the impairment of protein quality control machinery 
and oxidative stress [22,23].  In fact, factors such as mitochondrial dysfunction, oxidative stress, 
dysfunction of tau phosphorylation are not unique for AD. An intriguing hypothesis is that Ab is 
responsible for a chain reaction that triggers aberrant protein aggregation and overloads and impairs 
the “protein quality control machinery”, which is already normally impaired as age progresses. 
Therefore, this phenomenon leads to neuronal dysfunction and loss of function. Furthermore, it is 
also important to consider that AD is also characterized by a high comorbidity with other diseases 
that are commonly present during aging, such as diabetes, hypertension, sleep deprivation and 
others [24-26]. 
Consequently, understanding how to target biological cascades responsible for AD onset is 
crucial to design successful therapies, that will contribute to reduce the dramatic impact of 
Alzheimer’s disease on the society. In fact, due to the increase in elderly population, and the 
dramatic increase in people affected by AD that today cannot be cured, there is a prevalence of AD 
cases close to 40 million people worldwide [27]. Furthermore, the number of new cases is expected 
to increase by 2-fold every year and 16 million people affected by 2050 is the projection only in 
USA country [28]. Therefore, it is crucial to characterize biological cascades leading to the design 
of successful disease-modifying therapy. 
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II. Classification of Alzheimer’s disease pathologies 
 
AD pathologies can be classified in two main groups: familiar and sporadic AD. Familiar AD 
(fAD) is mainly caused by genetic factors. fAD characterizes only 5 % of all forms of AD and, 
interestingly, all mutations causing the disease involve either the gene encoding for the Amyloid 
precursor protein (APP) or genes encoding for enzymes involved in the APP processing [29-32]. 
Genetic mutations either involve genes for APP, presenilin1 and presenilin 2. Furthermore, fAD 
can be induced by an overexpression of APP and not only by mutations; trisomy 21 is one example. 
This evidence suggests a pivotal role of this cascade in the pathogenesis of AD pathology [27, 33-
36]. 
Differently from familiar AD, factors responsible for sporadic AD (sAD) are complex and 
heterogeneous. Moreover, the only genetic risk factor involves the ApoE e4 variant, which either 
leads to an alteration of encoded isoforms of the protein or to changes in epigenetic regulation of 
other genes, it is only responsible for an increased predisposition to contract the sAD, [37]. Only 
recently, genome-wide association analysis revealed the presence of at least 20 different genes, 
whose alteration might contribute to sAD, but with a very low impact in the risk to develop the 
disease. What seems to be the main reliable contribute to the onset of sAD is aging. Furthermore, 
if any, the inheritance is not mendelian, even though it might occur in about 60-70% of the cases. 
In addition, it has been observed DNA methylation as an early event in the AD pathogenesis as 
another possible factor contributing to the disease onset [29]. Furthermore, increasing literature 
supports the hypothesis that the accumulation of Ab is dramatically increased because of the critical 
impairment of clearance mechanisms [38]. 
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III. The role of Amyloid  b peptide in AD pathology 
 
On a biochemical level, AD has been defined as a “misfolding disease” [39, 40]. In fact, the 
main lesions characterized originally by Alzheimer in 1905, amyloid plaques and neurofibrillary 
tangles, are the product of misfolding and aggregation of the two most abundant proteins 
responsible for the onset of the disease: Amyloid b peptide (Ab) and hyperphosphorylated tau 
protein. Particularly, these proteins from a naïve conformation assume an “aggregation-prone” 
conformation that triggers an aggregation cascade and precipitation. Based on the evidence that 
familial AD can be caused either by APP overexpression or mutation of either processing sites in 
APP, or by mutations of genes encoding for some of the cleaving enzymes involved in APP 
processing, it has been proposed the high contribute to the disease of the amyloid cascade [27]. 
However, it is important to consider that the amyloid cascade is not the only driving mechanism 
leading to the disease and it is not the unique cause of the disease.  
Ab peptides are 36 to 43 a. a. long peptides that are produced by the cleavage of the Amyloid 
precursor protein (APP), a ubiquitous type-I oriented transmembrane protein constituted by 695 
residues [41]. In detail, Ab peptides are released because of two subsequent cleavages of APP 
protein, operated by b- and g-secretases This mechanism of processing is referred as “pro-
amyloidogenic pathway”. In fact, APP protein can be processed by two different cascades: “non-
amyloidogenic” and “pro-amyloidogenic”, summarized by the schematic in figure 2. Noteworthy, 
only the latter cascade is responsible for Ab release from the precursor APP. 
The non-amyloidogenic processing of APP is characterized by a cascade that does not produce 
Ab peptides, as the cleavage of APP by a-secretase is in the middle of the sequence that releases 
Ab, as summarized in the left panel of figure 2. Particularly, the first cleavage by a-secretase 
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generates C83 fragment that is further processed by g-secretase into p3 fragment that is not able to 
aggregate and not toxic. 
 
 
Figure 2. Schematic representation of the two main cleavage pathways of APP protein: non-amyloidogenic 
(let panel) and amyloidogenic (right panel) [42]. 
 
 
Conversely, as shown in the right panel of figure 2, in the pro-amyloidogenic pathway APP is 
first cleaved by b-secretase (BACE1) into C99 fragments and releases Ab peptide after g-secretase 
cleavage in the extracellular environment [42; 43]. The cascade leading to an increased Ab 
production can be further facilitated by an alteration of the balance between amyloid production 
and amyloid clearance, leading to the accumulation of neurotoxic species [44].  
The amyloid b peptide that is released by the pro-amyloidogenic pathway is characterized by 
an amorphous structure that makes the peptide prone to aggregate. The most abundant forms of 
human Ab are Ab1-40 and Ab1-42. Particularly, Ab1-42 is the most aggressive form for its pro-
amyloidogenic propensity given by the two amino acids isoleucine and alanine at the c-terminus 
[44, 45]. Particularly, the aggregation kinetic is characterized by a slow nucleation where small 
oligomers are formed (seeds), a step being the rate limiting of the whole reaction, and a fast 
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elongation, leading to the formation of well-organized fibers, due to the fast interaction of multiple 
Ab monomers with the growing seed [46]. Figure 3 summarizes the steps of Ab aggregation from 
a monomeric to a mature fibril structure. 
 
 
Figure 3. Schematic representation of aggregation kinetic Aβ peptide. Monomeric Aβ, once misfolded, initiates 
a nucleation phase, leading to the formation of toxic oligomers indicated by the red arrow. Oligomers further 
aggregate into protofibrils and mature fibrils during the elongation phase. Adapted from Kumar S. and Walter 
J., 2011 [47]. 
 
However, Ab aggregation of is far more complex than the cascade described in figure 3. In fact, 
the amorphic structure of Ab, due to a high abundance of intrinsically disordered regions, triggers 
several alternative pathways and leads to the formation of conformational different oligomers and 
aggregates [48, 49]. Despite all steps leading to the formation of amyloid structures, Alzheimer’s 
disease pathology correlates mainly with oligomeric intermediated of Ab, as demonstrated in vitro 
and in vivo [50-54]. Furthermore, it has been shown that oligomer toxicity is driven by their 
common conformation, even though the primary structure characterizing these oligomers might be 
of different peptides [55]. Additionally, it has also been observed the highest correlation between 
the pathogenesis of several neurodegenerative diseases and release of oligomers, thus suggesting 
the pivotal role of oligomeric structures for the onset of these diseases [56, 57]. 
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However, despite decades of research trying to understand what triggers Ab cascade, and how 
to block Ab-induced toxicity, research has been unsuccessful so far. One of the possible 
explanations could be related to the instability of oligomeric forms released during the aggregation 
kinetic, thus making so far impossible to design effective approaches against these forms. 
Therefore, it is crucial to design novel approaches that can effectively target this cascade. 
  
IV. AD pathology: Beyond amyloid  b peptide neurotoxicity 
 
The main hallmark of AD is protein misfolding, thus to be considered a like “prion-like” 
disease, even though AD is not characterized by infectious features, differently from prion diseases 
[58]. Even though it seems highly established the early contribute of Ab cascade to the onset of 
AD, recent studies suggest that Ab triggers the disease but does not accelerate the progression and 
is not the only factor responsible for the onset of neurodegeneration [22]. Moreover, it is important 
to mention that also mitochondria dysfunction and alteration of glucose metabolisms have been 
observed in both fAD and sAD very early during the progression of the disease. Particularly, it has 
been observed a positive link between ApoEe4 gene variant and alteration in glucose metabolism 
in AD and an increase of oxidative stress leading to cytochrome C release from mitochondria. 
Moreover, another evidence, suggesting the role of mitochondria alterations in AD, is the increased 
alteration in mitochondrial DNA leading to reactive oxygen species (ROS) accumulation [59]. 
Furthermore, it has also been observed a high accumulation of Ab in mitochondria, thus resulting 
into the alteration of electron transport chain and therefore alteration of metabolism. Indeed, the 
latter finding suggests a strong link between Ab toxicity and mitochondria dysfunction [60, 61].  
Another aspect involved in AD pathogenesis is tau pathology. In fact, even though tau hyper-
phosphorylation and oligomerization is not unique to AD, this alteration best correlates with 
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synaptic dysfunction and memory loss observed in AD brains. [62] Tau protein is the most abundant 
microtubule-associated protein and has the physiological role in stabilizing microtubules of axons 
[63]. As tau protein is altered by aberrant phosphorylation, subsequent tau misfolding and 
oligomerization is responsible for the spreading of these toxic species and neuronal loss [6].  
Overall, these considerations strongly support the concept that AD is triggered by a complex 
network of factors that together constitute a complex circuitry leading of the manifestation of AD 
pathology. A schematic representation of the possible pathways involved in AD onset and how risk 
factors might induce amyloid formation, tau propagation and neurodegeneration is summarized in 
figure 4. 
 
 
Figure 4. Schematic representation of the complex cascade leading to neurodegeneration in Alzheimer's 
disease [22]. 
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V. Alzheimer’s disease: Risk factors 
 
Depending on the form of Alzheimer’s disease, there are several risk factors that contribute to 
the AD onset. In fact, the “early onset” form of AD is mainly triggered by genetic factors, whereas 
the “late onset” form of AD has only one genetic risk factor that might contribute to a predisposition 
to contract the disease, and an incredibly long list of risk factors that are either biological, social or 
environmental. To know how risk factors are linked to the onset of the disease is important, as it 
allows to know in advance if there is a predisposition to the disease [64]. In detail, risk factors 
responsible for familiar AD (fAD) are mainly genetic and are mainly mutations involving APP or 
enzymes involved in the processing of APP (presenilin 1 or 2, BACE 1, BACE2 and nicastrin 
genes), or trisomy 21 However, fAD is responsible for a low percentage of AD cases, only 2%. 
[65]. Conversely, the most common form of AD, sporadic AD or sAD, can be facilitated genetically 
only by the presence of ApoEe4 gene variant and it is mainly influenced by environmental or 
biological factors. Example of non-genetic risk factors are: late age, cardiovascular disorders, type 
II diabetes, traumatic brain injury and more [64, 66]. Particularly, aging has a pivotal role in the 
pathogenesis in the most common for AD. In fact, during aging there are several biochemical 
changes, as oxidative stress, increased inflammation, mitochondrial dysfunction, impairment of the 
ubiquitin-proteasome system and chaperone machinery, thus facilitating the causative factor of AD: 
protein misfolding [67, 68]. Unfortunately, the mechanism responsible for triggering AD onset 
during aging in not fully understood, as these alterations that occur during aging have a high 
comorbidity with other diseases [69]. 
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VI. Therapeutic approaches 
 
AD is a known pathology for more than a century, however, all current therapies are not able 
to successfully cure this disease. In fact, the available therapies in the market only target certain 
phenotypes of the disease, but none of these approaches is a “disease-modifying” therapy. 
Currently, there are only two classes of FDA approved drugs, and few more compounds are only 
suggested adjuvants. One class of approved compounds is cholinesterase inhibitors (donepezil, 
galantamine and rivastigmine). The mechanism of action of these compounds is to increase 
acetylcholine levels through inhibiting cholinesterase action, an enzyme responsible for the 
degradation of the neurotransmitter and, therefore, potentiating this neuronal transmission. The use 
of this class of drugs is recommended mainly at initial stages of the disease, but it is also used in 
cases with moderate to severe AD either alone at higher doses or in combination with other drugs 
[70]. The mechanism of inhibition is either reversible (donepezil and galantamine) or pseudo-
irreversible (rivastigmine). The other FDA approved drug is a NMDA inhibitor, memantine, which 
is recommended for those cases with moderate to advanced pathology. The mechanism of action of 
this compounds involves the glutamatergic neurotransmission, and particularly binds NMDA 
receptor at the Mg2+ binding site, thus preventing an aberrant activation of the receptor by 
glutamate. However, the beneficial effect of this treatment for AD is not clear if is because of a 
symptomatic effect or because of the reduction of excitotoxicity that can be caused by a synaptic 
accumulation of calcium induced by an increased activity of NMDA receptors in the glutamatergic 
synapses [71]. The use of other drugs as adjuvants, i.e. COX inhibitors or vitamins (Vitamin E or 
Ascorbic acid), has been suggested to protect against the increase in neuro-inflammation that has 
been observed during AD. Unfortunately, AD is a multi-factorial disorder with an incredibly high 
level of comorbidity with other disorders, thus reflecting in a constant failure of any therapeutic 
approach tested. In fact, genic therapy seems to be an attractive perspective [4, 71].   
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AD is characterized by a very slow progression; therefore, an attractive strategy could be 
secondary prevention. The increased interest in designing specific antibodies or probes able to bind 
either amyloid beta or tau protein, seems a very promising pathway toward an early diagnosis of 
the disease. Some examples of recent trials activated aim to test the action of antibodies against Ab, 
particularly, solanezumab, gantenerumab and crenezumab. Moreover, other trials aimed to target 
enzymes involved in APP processing (g-secretase and BACE1). However, all trials so far failed 
either in phase II or phase III [72]. Therefore, there is an urgent need for effective therapies for AD 
as there are none available. 
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B. Chaperones: Relevance to aging and neurodegenerative disorders 
 
. 
I. Definition & Classification of Chaperones 
 
Chaperones are a class of ubiquitous proteins, that are highly conserved throughout evolution, 
and they are crucial for assisting the correct assembly of other newly synthesized proteins [73]. 
Moreover, these proteins are involved in the maintenance of protein and cell homeostasis 
throughout evolution [74]. Chaperones can be classified using several approaches. One example of 
classification is by molecular weight (MW) and this classification is summarized in table 1 [75]. 
Considering this specific classification, chaperones can be divided into: super-heavy (MW higher 
than 200 KDa), heavy (MW between 100-199 KDa), Hsp90s (MW between 81-99 KDa), 
Chaperones (MW between 65-80 KDa), Chaperonins (MW between 55-64 KDa), Hsp40 (MW 
between 35-54 KDa), small Hsps (MW less than 34 KDa) and other (various MW).  
 
 
Figure	5.	Classification	of	chaperones	by	molecular	weight	[75].	
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Attention is given to the class of “chaperonins”, as part of this thesis focuses on a chaperonin 
belonging to this sub-class: Heat shock protein 60 or Hsp60. Overall, this class of chaperones 
functions once organized into a “basket-like” oligomeric structure of 7-9 units. This structure allows 
to assist the folding of other proteins by offering a suitable and insulated environment for proper 
folding of native proteins, even though chaperones never take part into the final structure of assisted 
proteins. Therefore, chaperonins play a pivotal role in assisting other proteins even though they do 
not take part in the final structure of the protein itself [76, 77]. The mechanism of this class of 
chaperons, characterized by interaction with the substrate, internalization, refolding and release is 
usually ATP-dependent and will be describe more in detail in the following chapter. 
As chaperonins are a large group of chaperones with different properties, this class is further 
divided into two sub-classes: group I and group II. Group I chaperonins includes bacterial GroEL 
and eukaryotic Hsp60; group II chaperonins are thermosome expressed in Archaea or CCT and 
TRiC chaperonins found in cytosol of eukaryotes [78]. 
 
II. Structure-Activity Relationship of Chaperonins  
 
Chaperonins have a pivotal function in preventing protein aggregation though the assistance of 
the correct protein folding [79, 80]. The general mechanism is though the ability of offering a 
hydrophobic chamber in which a substrate can access to and refold faster and in absence of crowded 
environment of cytosolic compartment. Furthermore, it has been also observed that chaperonins 
can interact with proteins that are larger than the “folding cavity” and prevent their aggregation, 
thus suggesting alternative mechanisms of action [81]. Indeed, chaperones’ ability to interact with 
their substrate thanks to the presence of “intrinsically disordered regions” (IDRs) [82]. These 
regions are characterized by extended molecular configuration, poor or absent secondary structure 
and absence of a defined tertiary structure and therefore are characterized by high flexibility [83-
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85]. Indeed, these regions are the active site of the chaperone that allow the interaction with their 
substrate and allow the mechanism of action that is characterized by the recognition of the substrate, 
the assembly and the ability of modify the structure of other proteins [86].  
The general structure of class I chaperonins can be summarized using GroEL as a model. In 
detail, the oligomer-forming unit has a secondary structure that is characterized by three main 
domains: apical, intermediate and e equatorial domains. The apical domain is essential for the 
formation of the pore to the folding cavity; the intermediate domain contributes to the overall 
flexibility of the structure and provides a connecting bridge between the other two domains; the 
equatorial domain is involved in interactions both within and between rings [87]. To be active, class 
I chaperonins are organized in a double ring complex, which is constituted by the assembly of two 
homo-heptameric oligomers. This three-dimensional conformation allows the formation of an inner 
hydrophobic cavity large about 45 Å, defined as the “folding chamber”. Moreover, this cavity 
becomes even larger when the chaperone is in its active state and bound to ATP and the co-chaperon 
GroES, which constitutes the lid of the folding chamber. [88]. The mechanism of action of the 
chaperone is allowed by the positive cooperativity within rings, the negative cooperativity between 
rings, both ATP-dependent, and a mechanism of cyclic conformational changes [78]. 
The mechanism of action of class I chaperonins is also described using as a model the well-
studied GroEL-GroES cycle. Particularly, GroEL assembles in a double-ring tetradecameric 
oligomer interacts with GroES or its substrates on the apical domain [89]. Indeed, the proper folding 
of substrate occurs because of a series of conformational changes of the chaperone complex. As 
summarized in figure 6, GroEL facilitates the proper folding of the substrate once assembled in an 
oligomeric complex and bound to 7 ATP molecules at the equatorial domain and GroES at the 
apical domain. In fact, after the formation of this complex the substrate can enter into the chaperone 
cavity, which is enlarged by conformational changes of the heteromeric complex. The release of 
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the newly folded substrate occurs upon ATP hydrolysis and ADP release. Overall, this mechanism 
has been referred to the model of an “Anfisen cage” [90]. ATP binding is important to trigger the 
cascade that leads to the complex formation with GroES and to the internalization of the protein 
that needs to be folded. Moreover, ATP binding is also involved in the activation of the second ring 
of the chaperone which triggers a new process of folding. ATP cleavage is important to facilitate 
the removal of GroES and the release of the newly folded protein. However, only one chamber at 
the time is active [91]. 
 
 
Figure 6. Mechanism chaperone’s folding cycle. A chaperone can interact with a specific substrate in presence 
of ATP. The refolding of the substrate occurs in the folding chamber organized by the chaperone cavity and 
the binding of the co-chaperone. As the substrate and ADP are released, the chaperone can start a new cycle 
in the second chamber. Adapted from Skjærven et al., 2015 [78]. 
 
Human Hsp60 is a mitochondrial chaperone that is synthesized in the nucleus as a longer 
inactive form. Human Hsp60, despite the homology with the bacterial form, is structurally different, 
as it is organized by either 7 or 14 units which form either a single ring (heptameric conformation) 
or a double ring (tetradecamer) [92]. The 26 amino acids long sequence is referred as “leader 
sequence” that is important for mitochondria import. The mechanism of import of the chaperone is 
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highly organized and requires the presence of other chaperones in the matrix space and the correct 
membrane potential. The cleaved form of Hsp60 becomes active into the mitochondria via ATP-
dependent process of oligomerization that is guided by other pre-existing Hsp60 oligomers [93]. 
The shorter and active form of Hsp60 works mainly into the mitochondria, even though action 
of Hsp60 has been observed also in the cytosol as pro-apoptotic mediation because of the action on 
the pro-caspase 3 [94]. 
Other functions of chaperonins are to control and minimize cellular stress due to environment 
stress, such as increased temperature, pH change or other stressors. Furthermore, chaperonins are 
also regulators of homeostatic functions, such as apoptosis, control of oxidative stress cascade, 
cooperate with the ubiquitin-proteasome degradation machinery [95]. 
Group II chaperones are characterized by higher complexity if compared to class I.  In fact, 
despite the similar organization of oligomer-forming unit in domains, differently from group I, they 
from complex of 8 or 9 monomers and the oligomeric structure is mainly heteromeric, even though 
the interactions within and between subunits are not fully understood. Moreover, the mechanism of 
signaling between rings seems different between the two groups [96]. However, the mechanism of 
action of this group of chaperones is same as group I, as it is characterized by similar steps: 
formation of chaperone complex, ATP binding, interaction with the substrate in the open state, 
folding of the substrate in closing conformation and release of the folded substrate. However, data 
suggests a higher level of specialization and complexity due to the “functional polarity” of these 
types of chaperones. Moreover, it has been suggested a substrate-specificity for these chaperones, 
differently from group I [78]. 
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III. Chaperones & Neurodegenerative diseases 
 
Chaperones are one of the most conserved guardians of cellular proteome and increasing 
evidence supports their important role in keeping cellular homeostasis, targeting dysfunctional 
proteins and facilitating the removal of toxic stressors [91, 97]. On a cellular level, proteins are 
exposed to crowded environments and any alteration of the balance between protective and 
damaging factors might induce protein dysfunction. Moreover, aging is the first factor responsible 
for an impairment of protective factors due to the physiological reduction of “proteostasis network” 
[97]. Therefore, it is not surprising that aging is the major risk factors of several pathologies 
characterized by protein misfolding or cancer. In fact, alterations of chaperone network have been 
associated with several diseases: amyotrophic lateral sclerosis, retinal degenerative disease, 
peripheral neuropathies and Alzheimer’s disease [98]. Therefore, loss of function of chaperones 
have been suggested as one of the contributors in AD pathogenesis. Indeed, these proteins could be 
a potential target for future therapies. Noteworthy, the study showing that to potentiate the 
chaperone machinery in an in vitro model of amyloid pathology reduces Ab-driven cytotoxicity 
and mitochondrial dysfunction [99]. However, there are mechanisms linking the role of chaperones 
and protein dysfunction observed in AD that needs further clarification, as for the presence of some 
controversies in the field. In fact, a gain of toxicity of certain chaperones in AD, thus resulting in 
an enhancement of Ab toxicity, it has also been proposed [100]. Moreover, it has also been shown 
a correlation between certain proteinopathies, as polyglutamine disease, with age-related decline of 
the protein quality control machinery [101]. 
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Aim of the dissertation 
 
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Moreover, there is a 
complex etiology responsible for the onset of AD, thus making so far impossible to find effective 
disease-modifying therapies. There are several hypotheses suggesting possible mechanisms 
involved in AD onset, however, the pro-amyloidogenic cleavage of amyloid precursor protein 
(APP), leading to amyloid beta peptide (Ab) formation, misfolding and subsequent neurotoxicity, 
seems one of the most accredited. Moreover, there is evidence suggesting that a failure of the 
protein quality control machinery also contributes to AD onset, thus confirming that the main risk 
factor of late onset AD is aging. One important component of the protein quality control machinery 
is the family of chaperones, particularly, the focus of my thesis in one of the most evolutionary 
conserved chaperone: Hsp60. This mitochondrial chaperonin is involved both in protecting 
mitochondria from damage induced by misfolded protein on a cellular level, and in a cross-talk 
with the immune system on a systemic level. Additionally, it has been shown that Hsp60 is directly 
involved in an interaction with APP/Ab and in a downstream protection of mitochondria from Ab-
induced damage. Therefore, the aim of this dissertation is to determine the functional effect of 
Hsp60 on Ab, either in its monomeric or oligomeric structure, and to investigate if this interaction 
leads to the formation of less toxic conformations. My central hypothesis is that Hsp60 effectively 
inhibits Ab aggregation and toxicity. I addressed my central hypothesis with three specific aims. I 
first confirmed that Hsp60 has a direct effect in inhibiting the aggregation of Ab using a cell free 
system. I addressed my aim using circular dichroism, Thioflavin T assay, size exclusion 
chromatography and atomic force microscopy. In my second specific aim, I tested the working 
hypothesis that to overexpress Hsp60 influences APP processing and Ab release using an in vitro 
approach. I addressed my second aim creating a novel cellular model that overexpresses both the 
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amyloid precursor protein (APP) and Hsp60 and, as I validated the model by western blotting and 
immunocytochemistry, I investigated the effect of Hsp60 on APP and Ab in different sub-cellular 
compartments: extracellular, intracellular and mitochondria. Finally, in my third aim, I confirmed 
that, upon Hsp60 treatment, Ab formed less toxic oligomers, thus resulting in reduction in neuronal 
death in vitro. I addressed my third aim using a neuroblastoma cell line as an in vitro model, and I 
tested changes in cytotoxicity of either human Ab oligomers produced in vitro or pre-formed 
oligomers, both before and after Hsp60 exposure. I parallel experiments, I investigated the levels 
of Hsp60 in post mortem tissues of Alzheimer’s disease individuals, compared to healthy controls, 
using western blotting to confirm that during Alzheimer’s disease there is an impairment of the 
chaperone machinery, with attention to Hsp60. As the field is controversial about the role of Hsp60 
in AD, this project will contribute to elucidate crucial mechanisms of action of Hsp60, thus 
proposing this chaperone as a potential target for future therapies against AD pathology.  
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Experimental approach 
I. Material and Methods 
-Amyloid b peptides: Ab1-40 (Anaspec) preparation for biophysical analysis is using a 
standardized protocol published by Fezoui et al. [102]. In detail, the peptide was solubilized in 
NaOH 5 mM (pH 10) and aliquots deeply frozen in liquid nitrogen, lyophilized and stored at -80 
°C upon use. Before each experiment, lyophilized aliquots were solubilized in Tris HCl 20 mM (pH 
7.7), and filtered using to filtered installed in series with 0.20 µm (Whatman) and 0.02 µm (Millex-
Lg) respectively, to remove larger aggregates or impurities. All procedures were done in a cold 
room kept at 4 °C. The initial concentration of the sample was determined spectrophotometrically 
per Lambert-Beer equation using tyrosine absorption at 276 nm and a molar extinction coefficient 
of 1390 cm-1 M-1 [103]. All aggregation kinetics were performed at controlled temperature (37 °C) 
and agitation (200 rpm) for a total time of 24 hours. Aliquots of Ab1-40 used for SEC-HPLC 
injections were concentrated after chromatographic elution with 3 KDa cut-off filters (Millipore) 
by centrifugation at 6000g and 5 °C, using a centrifuge Heraeus Multifuge X3R. Samples of Ab1-
40 50 uM for AFM measurements, either treated or not with Hsp60 2uM, were adsorbed on MICA 
surface either at time 0 or after 3 days of the aggregation kinetic.  Ab1-42 monomers, for experiments 
of aggregation kinetics in cell free system, were produced from a recombinant peptide produced 
and purified as previously described [104]. Frozen lyophilized fractions were then prepared using 
the same protocol used for Ab1-40 as previously described. The aggregation kinetic was performed 
either using a final concentration of 50 µM or 15 µM. The concentration chosen to test the effect 
of Hsp60 was 15 µM, due to the high aggregation rate of this peptide. 
Ab oligomers for in vitro experiments per prepared as previously published [53]. Briefly, 1 mg 
of lyophilized peptide is solubilized in 1.5 ml acetonitrile/water 1:1 (v/v), to remove impurities. 
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The suspension is left room temperature for 10-15 minutes and aliquoted into three 1 ml tubes 
(Eppendorf) and further lyophilized and stored at -20 °C upon use. The day of the experiment 
aliquots are suspended in Hexafluoro-2-propanol, HFIP (200  µL for each aliquot used) and left at 
room temperature for 10-20 minutes. The solution is then transferred in a new tube with a stirrer 
and diluted with DDI water (700 µL for each aliquot), gently mixed and covered with a cap with 
holes. The peptide is left oligomerize at room temperature and under agitation for 2 days. Oligomers 
are either used immediately or stored at -80 °C until use. The quality of Ab oligomers is confirmed 
by dot blot assay using either 6E10 (mouse, Covange) antibody or A11 (rabbit, Covance).   
-Hsp60: for biophysics experiments, human variant of mitochondrial Hsp60 (short form, 
ATGen), was subjected to buffer change from 20 mM Tris HCl (pH 8), 100 mM NaCl, 10% 
Glycerol to the desired final buffer using centrifuge filtering devices with a 30 KDa cut-off (Amicon 
Ultra 4, Millipore). Final conditions were the following: 20 mM Tris HCl (pH 7.7), 30 mM NaCl, 
3% Glycerol. Prior to each experiment, protein stability was estimated using light scattering 
technique. For cell culture experiments, aliquots of Hsp60 were diluted up to 2 µM or 1 µM in 
buffer PBS 1X and further diluted in DMEM/F12 up to 10 times for cytotoxicity experiments. All 
sample preparation procedures were conducted in asepsis. All samples’ final concentrations were 
calculated mathematically and final samples prepared either in cold room or in ice. 
-Thioflavin T Assay. Thioflavin T (ThT) is a benzothiazolic compound used to detect amyloid 
aggregation for the ability to fluoresce in presence of b-sheet rich structures, as the two aromatic 
rings of its chemical structure becomes more conjugated in presence of fibers and therefore 
contributes to an increase in intensity of emission [105]. All experiments are performed using ThT 
12 µM added to sample aliquots and emission spectra recorded with a JASCO FP-6500 
spectrophotometer. In all experiments excitation wavelength was 450 nm and kinetic of emission 
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was acquired at 485 nm. Slit width was fixed at 3 nm. All samples were incubated at 37 °C and 
stirred at 200 rpm [106]. 
-Circular Dichroism (CD) spectroscopy. The use of this spectroscopic technique allows to 
characterize the secondary structure and the three-dimensionality of proteins, due to the 
asymmetrical structure and therefore its different ability to interfere with circularly polarized light 
[107]. All CD spectra are measured using a JASCO J-815 CD spectrometer on a small aliquot of 
sample (50 µL) loaded on a 0.2 mm path length quartz cuvette. All recordings were done at 20 °C 
and each spectrum showed in the results section is the average of 8 scans and the result of solvent 
subtraction [106].   
-Atomic Force Microscopy. Morphology information of samples of either Ab1-40 or Ab1-40 
exposed to Hsp60 were obtained thanks to a collaboration with the “Istituto Italiano di Tecnologie” 
in Genoa (IT), using a Nanowizard III (JPK Instruments, Germany) either mounted on a Axio 
Observer D1 (Carl Zeiss, Germany) or on an Eclips Ti (Nikon, Japan) microscopes. For each 
sample, small aliquots were adsorbed on a freshly cleaved mica surface (Agar Scientific, Assing) 
for 20 minutes, washed with deionized water and dried with pressurized nitrogen. The morphology 
of each sample was obtained using an “intermittent contact mode in air”, using a NCHR silicon 
cantilever (Nanoworld). The nominal spring constant ranged between 21 and 78 N/m and the 
resonance frequency between 250 and 390 kHrz [106]. 
-HPLC. All chromatographic analyses were done using a HPLC machine (Prominence, 
Shimatzu) assembled with a mobile phase degasser (DGU-20As), a quaternary pump (LC-2010 
AT) and 500 µL injection loop. To elute samples by size, Superdex 200 (10 300 GE Healthcare) 
column was used to separate samples, and as mobile phase 20 mM Tris HCl (pH 7.7), 3 % glycerol, 
30 mM NaCl. Flow rate for samples elution was controlled at 0.5 mL/min-1. Samples detection was 
done using a photodiode array detector (SPD-M20A) and chromatograms recorded at 280 nm [106]. 
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-Cell culture. Chinese Hamster Ovary cells (CHO) and 7PA2 cell line, CHO overexpressing 
human APP variant with the Swedish mutation were generously donated by Dr. Dennis Selkoe at 
Harvard Medical School, Boston, MA, kindly donated from Selkoe DJ at Harvard, USA) were kept 
in culture for less than 10 passages with DMEM (Corning), 10% FBS (heat inactivated 15 minute, 
56 °C, Sigma Aldrich), 1% penicillin/streptomycin (Gibco), without (CHO cells) or with G418 
(7PA2 cells, Gibco). 7PA2/H60 cell line was kept in culture for less than 10 passages with DMEM 
(Corning), 10% FBS (heat inactivated 15 minute, 56 °C, Sigma Aldrich), 1% 
penicillin/streptomycin (Gibco), G418 0.6 mg/mL and Hygromicin B (Corning) 0.6 mg/ml. SH-
SY5Y neuroblastoma cell line was grown in DMEM/F12 (Corning), 10% FBS (heat inactivated 15 
minute, 56 °C, Sigma Aldrich), 1% penicillin/streptomycin (Gibco) and cells were seeded on a 24- 
or 96-wells plates, the day before each treatment in regular media end treatments were given in 
DMEM/F12 for 24 hours. 
-Sub-cellular fractionation: Mitochondria were isolated using a preparation kit [Qproteome, 
Mitochondria isolation kit, Qiagen] and the quality of the preparation validated by western blotting; 
extracellular environment was isolated using a protocol optimized for obtaining a media enriched 
in Ab, referred as “conditioned media” (CM) using a revised protocol published by Meli et al. 
[108]. 
-Plasmid transfection: Overexpression of plasmids, either empty pCMV6 or pCMV6-Hsp60 
(both OriGene), has been done with Lipofectamine 2000 (Life technologies, Protocol Pub. No. 
MAN0007824 Rev.1.0) using manufacturer’s recommended protocol [109]. In detail, one day prior 
to transfection, cells were seeded to be 70% confluent at moment of transfection. Concentrations 
of lipofectamine and plasmids were optimized to obtain a high transfection efficiency. Prior 
transfection, lipofectamine was diluted and mixtures left 10 minutes at room temperature. 
Subsequently cDNA at proper concentration was added to lipid complex and reaction between 
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reagents allowed for further 10 minutes. Transfection of cells was blocked after 5 hours with media 
enriched with serum and antibiotics free. After 24 hours, cells are washed and initial media replaced 
with antibiotics-enriched media. Efficiency of transfection was tested either 48 hours or after 1 
month of transfection by western blotting and immunocytochemistry as described below.    
- Cytotoxicity Assay. Cell death was measured after 24 hours’ treatments using the 
“Cytotoxicity Assay kit” (Roche) and procedures were done using manufacturer protocol. Briefly, 
cytotoxicity is calculated as the function of absorbance of a dye sensitive di lactate dehydrogenase 
released un the culture media by damaged cells. The colorimetric reaction is then detected by a 
multiplate reader (µQuant, Biotek) and cytotoxicity calculated as a percentage using the following 
formula: Cytotoxicity (%)= [(experimental value – low control)/ (high control – low control)] *100. 
Low control was calculated using media from cells treated with serum-free culture media 
(DMEM/F12 medium, Sigma Aldrich); high control was calculated using media from cells treated 
with 10% Triton-X 100 serum free culture media. All samples used for cell treatments were diluted 
1:10 or 1:5 in serum-free culture media. Cells were treated either with oligomers, Hsp60, oligomers 
exposed to Hsp60, 7PA2 CM, CHO conditioned media (CM), 7PA2 CM or 7PA2/H60 CM.  
- Western Blotting (WB). All blots were done in denaturing conditions. Electrophoretic run 
is performed at constant voltage (100 V for 10 minutes and 120 V until the end of the run). Protein 
were transferred on a nitrocellulose membrane at 0.4 A for 1 hour 30 minutes in ice or 0.02 A for 
18 hours if total proteins loaded was equal to or higher than 100 µg. Antigen retrieval was then 
performed by microwaving the membrane in PBS buffer 1 minute and then 30 seconds after a wash 
of 4 minutes in fresh PBS. Proper transfer of the proteins was assessed with Ponceau Red and 
membranes were then blocked with Odyssey blocking solution at room temperature for 1 hour. 
6E10 (1:1000, Covance) has been used to detect APP; anti-Hsp60 (1:5000, Abcam) has been used 
to detect the total amount of Hsp60 expressed; DDK antibody (1:1000, OriGene) has been used to 
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detect the recombinant protein overexpressed after plasmid transfection. Blots acquisition were 
performed with Odyssey LI-COR using manufacturer’s protocol and quantifications were obtained 
with ImageJ software. 
- Immunocytochemistry (ICC). All confocal images have been done on fixed cells with 
methanol/acetone and mounted on Super/frost slides (Fisherbrand, Fisher scientific), using a Nikon 
A1+ confocal microscope. Cells were seeded on coverslips 24 hours prior to immunocytochemistry 
and washed twice with cold PSB. Cells were then fixed and left 1 hour on ice. Cells were then 
washed twice for 5 minutes with cold PBS and blocked 1 hours with 3% BSA and 0.05% Tween 
20 in PBS. All primary antibodies were incubated for 18 hours at 5 ºC and secondary antibodies 
were incubated 1 hour at room temperature away from light, after two 10 minutes’ washes with 
PBS. In detail, nuclei are stained with DAPI, Aβ/APP is stained with 6E10 antibody (mouse, 
Covance), total Hsp60 is stained with anti-Hsp60 antibody (rabbit, Abcam or Origene), 
recombinant Hsp60 is stained with anti-DDK antibodies (mouse Origene o rabbit, Santacruz). 
Secondary antibodies are Alexa-594 (red, mouse or rabbit, Abcam), Alexa-488 (green, mouse or 
rabbit, Abcam). All antibodies were properly diluted in PBS 1.5% normal goat serum (NGS) 
- ELISA. Quantitative analysis of total Aβ was done using manufacturer protocol for Human 
Aβ42 ELISA kit (life technologies) on culture media isolated from CHO, 7PA2 and 7PA2/H60 cell 
lines and prepared following a revised protocol published Meli G. et al. 2014 [108]. 
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II. Results 
1. Investigating the inhibitory effect of Hsp60 on Ab aggregation using a “cell 
free” model.  
 
 
- Hsp60- Ab1-40 protein/protein interaction in a cell free system: model validation 
I first tested the hypothesis that Hsp60 successfully inhibits Ab1-40 aggregation. To support my 
hypothesis, I first characterized all optimal conditions for testing a correct protein-protein 
interaction in a cell free model. The rationale of this investigation lays on the principle that the 
physical interaction between Ab1-40 and Hsp60 is known in literature, as immunoprecipitation data 
(IP) has been previously reported [100]. However, the mechanism of interaction between these two 
proteins is not fully understood. Table 1 summarizes the concentrations tested of both Ab1-40 peptide 
and Hsp60, and buffer composition used to solubilize both peptides. Particularly, I tested Ab1-40 50 
µM and 25 µM either without or exposed to the mitochondrial form of Hsp60 (short Hsp60 or 
Hsp60s) at 1 µM or 2 µM concentrations. The approach I used to test the effect of Hsp60 on Ab1-40 
aggregation is based on a well characterized protocol of amyloid b aggregation [110, 111], which 
allowed a controlled aggregation kinetic toward fiber formation. In summary, the aggregation 
kinetic was controlled for a time of at least 24 hours under constant temperature of 37 °C and 
agitation of 200 rpm. Each condition used is summarized in table 1 and each sample was tested 
using Thioflavin T assay and CD measurements of time points of the aggregation kinetic, as these 
were very well established assays for characterizing Ab1-40 aggregation kinetic.  Particularly, it has 
been already described in material and methods that ThT is a probe whose fluorescence increased 
in presence of aggregates in solution, for a conformational flexibility that allowed an increased 
conjugation in presence of amyloid fibers. Therefore, this was a valid and reproducible technique 
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for the indirect measure of Ab1-40 aggregation kinetic. On the other hands, circular dichroism gave 
direct information about the folding state of the proteins analyzed, due to the specific interaction 
between the asymmetrical conformation of the protein and the circularly polarized light of the 
instrument. 
 
Table 1. Optimization of working conditions for testing Ab-Hsp60 interaction 
Conditions 1 2 3 4 5 6 7 8 
[Ab1-40] 50 µM 50 µM 50 µM 50 µM 25 µM 50 µM - - 
[Hsp60s] - 1 µM - 2 µM - 2 µM 1 µM 2 µM 
Buffer 20 mM 
Tris 
HCl 
20 mM 
Tris HCl, 
1.5% 
glycerol, 
15 mM 
NaCl 
20 mM 
Tris HCl  
3% 
glycerol, 
30 mM 
NaCl 
20 mM 
Tris HCl, 
3% 
glycerol, 
30 mM 
NaCl 
20 mM 
Tris HCl, 
10% 
glycerol, 
100 mM 
NaCl 
20 mM 
Tris HCl, 
10% 
glycerol, 
100 mM 
NaCl 
20 mM 
Tris 
HCl, 
1.5% 
glycerol, 
15 mM 
NaCl 
20 mM 
Tris HCl, 
10% 
glycerol, 
100 mM 
NaCl 
rpm 200 200 200 200 200 200 200 200 
pH 7.4 7.4 7.4 7.4 7.4 7.4 7.4 7.4 
T 37 °C 37 °C 37 °C 37 °C 37 °C 37 °C 37 °C 37 °C 
[ThT] 12 µM 12 µM 12 µM 12 µM 12 µM 12 µM 12 µM 12 µM 
 
However, it was important to consider that, even though the main goal of using CD technique 
was to characterize Ab secondary structure, also Hsp60 had a signal in the range of wavelengths in 
which Ab absorbs. In fact, figure 7 shows a kinetic of Hsp60 2 µM at different time points (0, 1, 3, 
and 5 hours) and it is possible to observe the intense alpha-helix signal that is stable over time and 
that could cover structural information given by Ab peptide spectra. Therefore, all CD spectra of 
Ab1-40 and Hsp60 kinetics reported in the following chapter were presented subtracting the 
contribute Hsp60 CD spectrum.  
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Figure 7. CD spectra of Hsp60 2 µM at different time points of an incubation kinetic: 0 (black dotted line); 1 
hour (green dotted line); 3 hours (red dotted line); 5 hours (blue dotted line). Experimental conditions: buffer 
20 mM Tris (pH= 7.7), 3% glycerol, 30 mM NaCl, T = 20 °C. 
 
Figure 8 shows both ThT assay (panel A on the left) and CD spectra (panel B on the right) on 5 
time points of the aggregation kinetic of a sample of Ab1-40 50 µM in 20 mM Tris HCl buffer (pH 
7.4), time 0, 1 hour, 3 hours, 5 hours and 24 hours. Consistent with the extensive literature available 
[112-114], time course fluorescence of ThT was characterized by an initial low signal referred as 
lag phase, representing the nucleation phase of Ab seeds, followed by an exponential increase in 
intensity of emission until a plateau, representing the elongation phase of aggregates and the 
formation of amyloid fibers. In these conditions of temperature, buffer, pH and agitation, Ab fibers 
were formed in about 6 hours. In fact, at time 0 of the aggregation kinetic the CD spectrum of the 
protein (black spectrum, figure 8) was characterized by a minimum around 195 nm, which was 
typical of a random coil conformation characterizing unordered and not aggregated structures. As 
soon as Ab was incubated under pro-aggregating conditions, there was a change in its CD spectrum 
that already after 5 hours (blue spectrum) was characterized by a shift of the minimum around 210 
nm, typical of b-sheet conformations of aggregated proteins. The aggregation of Ab is even more 
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pronounced after 24 hours (light blue spectrum, figure 8 B), as the CD spectrum is characterized by 
a shape of a sigmoid with two minima in the range on 215 nm and 220 nm respectively.  
 
 
Figure 8.  Characterization of Ab1-40 aggregation kinetic using ThT and CD assays. A. ThT assay of Ab1-40 
in 20 mM Tris HCl buffer (pH 7.7) incubated at 37 ∘ C and stirred at 200 rpm in presence of ThT.  lxcThT=450 
nm; lemThT=484 nm. B. CD spectra of Ab1-40 at different time points of the aggregation kinetic: 0 (black 
line), 1 hour (green line), 3 hours (red line), 5 hours (blue line) and 24 hours (light blue line). Measures 
recorded at 20 ∘ C. 
 
Once defined the biophysics properties of Ab1-40 50 µM in this specific experimental conditions, 
I tested the effect of different concentrations of Hsp60 (1 µM and 2 µM respectively) on the 
aggregation kinetic using the same techniques: ThT assay and CD analysis at specific time points 
as previously described. As summarized in figure 9, in these experimental conditions, Hsp60 1 µM 
influenced Ab1-40 aggregation kinetic, as it was possible to observe a longer lag phase with the ThT 
assay (panel A, figure 9), which suggested a change in the nucleation phase. In addition, CD spectra 
of time points of the aggregation kinetic suggested that the presence of Hsp60 inhibited Ab 
aggregation when compared to Ab1-40 alone (panel B, figure 9). Particularly, it was possible to 
observe that CD spectrum at 3 hours of Ab1-40 treated with Hsp60 under pro-aggregating conditions 
(red spectrum, figure 9B) had a similar morphology of monomeric Ab1-40 at (black spectrum figure 
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9 B). On the other hands, untreated Ab1-40 spectrum after 3 hours (dotted spectrum in red, figure 
9B) had a different morphology compared to time zero, thus suggesting aggregates formation. The 
difference in conformation of Ab1-40 treated with Hsp60 was even more pronounced if compared 
CD spectra at 5 hours of aggregation kinetic (blue continuous line compared to blue dotted line, 
figure 9B). 
 
 
Figure 9. Characterization of Aβ1-40 aggregation kinetic with Hsp60 1𝜇M using ThT and CD assays. A. ThT 
assay suggests that the presence Hsp60 delays the aggregation kinetic (red line) compared to the control (blue 
time point). Both kinetics is performed in 20 mM Tris HCl buffer, 1.5 % glycerol, 15 mM NaCl (pH 7.7), T = 
37 ∘C, agitation 200 rpm, ThT 12 µM. lexcThT=450 nm; lemThT=484 nm. B. CD spectra of Aβ1-40 50𝜇M 
with Hsp60 1𝜇M at different time points of the aggregation kinetic: 0 hour (black line), 1 hour (green line), 3 
hours (red line), 5 hours (blue line), compared to Aβ1-40 kinetic: 1 hour (green dotted line), 3 hours (red dotted 
line), 5 hours (blue dotted line). Data suggests a change in Aβ conformation in presence of Hsp60, due to a 
delay of aggregation. Measures done at 20 ∘C. 
 
Moreover, I wanted to investigate if an increase of Hsp60 concentration could completely 
inhibit Ab1-40 aggregation kinetic. Therefore, a sample of Ab1-40 50 µM was either exposed or not 
to Hsp60 2 µM in buffer 20 mM Tris HCl (pH 7.7), 10% glycerol and 100 mM NaCl (figure 10). 
As confirmed by ThT assay in figure 10A, Hsp60 in these conditions successfully delayed the 
nucleation phase of amyloid beta kinetic, even though the formation of fibers was not inhibited. 
However, it is known from literature that high ionic strength is a factor facilitating protein 
  39 
aggregation. Therefore, I tested the same concentration of the two proteins but in milder conditions: 
20 mMTris HCl pH 7.4, 3% glycerol, 30 mM NaCl. Results are shown in figure 11.  
 
 
Figure 10. Characterization of aggregation kinetic of Aβ1-40 50𝜇M with Hsp60 2𝜇M in high salt concentration 
buffer, using ThT and CD assays. A. ThT assay suggests that Hsp60 delays Aβ aggregation kinetic (red line) 
compared to the control (blue line). Both kinetics is performed in 20 mM Tris HCl buffer, 10 % glycerol, 100 
mM NaCl (pH 7.7), T = 37 ∘C, agitation and 200 rpm, ThT 12 µM. lexcThT=450 nm; lemThT=484 nm. B. 
CD spectra of Aβ1-40 50𝜇M with Hsp60 2𝜇M at different time points of the aggregation kinetic: 0 hour (black 
line), 1 hour (green line), 3 hours (red line), 5 hours (blue line), compared to Aβ1-40 50𝜇M kinetic: 0 hour 
(black dotted line), 1 hour (green dotted line), 3 hours (red dotted line), 5 hours (blue dotted line). Data 
suggests a change in Aβ conformation in presence of Hsp60, due to a delay of aggregation. Measures done at 
20 ∘C. 
 
Interestingly, in these conditions Hsp60 had a very strong effect in blocking Ab1-40 aggregation 
kinetic. In fact, as summarized in figure 11, panel A, ThT assay of Ab1-40 treated with Hsp60 2 µM 
(red line, figure 11 A) did not form seeds able to trigger the exponential aggregation phase, as 
observed in the untreated Ab1-40 sample (blue line, figure 11 A). Therefore, this data suggested that 
Ab1-40 exposed to Hsp60 lost the ability to aggregate. This data was further confirmed by CD 
analysis summarized in Figure 11 panels B and C. Particularly, in figure 11 B are compared CD 
spectra of Ab1-40 either with or without Hsp60 at time zero, 1 hour, 3 hours and 5 hours. Moreover, 
in figure 11 C are compared CD spectra of both proteins at time zero and 24 hours. Overall, CD 
spectra analysis suggested that Hasp60 inhibited Ab1-40 aggregation, because the presence of the 
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chaperone changes Ab spectrum morphology. Particularly, the phenomenon is clear when 
compared to the untreated peptide at the time point of 24 hours (dotted red line compared to red 
line in figure 11 C). 
 
 
Figure 11. Characterization of aggregation kinetic of Aβ1-40 50 𝜇M with Hsp60 2𝜇M using ThT and CD 
assays. A. ThT assay suggests Hsp60 inhibits Aβ aggregation kinetic (red line) compared to the control (blue 
time point). Both kinetics is performed in 20 mM Tris HCl buffer, 3 % glycerol, 30 mM NaCl (pH 7.7), T= 37 
∘C, agitation 200 rpm, agitation ThT 12	𝜇M. lexcThT=450 nm; lemThT=484 nm. B. CD spectra of Aβ1-40 50𝜇M 
with Hsp60 2𝜇M at different time points of the aggregation kinetic: 0 hour (black line), 1 hour (green line), 3 
hours (red line), 5 hours (blue line), compared to Aβ1-40 50𝜇M kinetic: 0 (black dotted line), 1 hour (green 
dotted line), 3 hours (red dotted line), 5 hours (blue dotted line). Data suggests a change in Aβ conformation 
in presence of Hsp60, due to a delay of aggregation. All CD spectra are performed at 20 ∘C. C. CD spectra of 
Aβ1-40 50𝜇M with Hsp60 2𝜇M, compared to Aβ only, at time zero (black lines) or after 3 days (red lines). 
 
- Hsp60- Ab1-40 protein/protein interaction in a cell free system: AFM morphology 
To further validate the effect of Hsp60 on Ab1-40 aggregation, samples of Ab1-40, either exposed 
or not Hsp60 were analyzed with atomic force microscopy (AFM) for morphologic characterization 
at time zero and after 24 hours of aggregation kinetic. Data summarized in figure 12 were done in 
collaboration with ITC in Genova by Dr. Canale. In detail, consistent with data from several other 
laboratories, as Ab1-40 is under pro-aggregating conditions for 24 hours, it formed long fibers that 
were in the range of microns (figure 12 panels a and b). Consistent with CD and ThT assays 
previously shown, the presence of Hsp60 completely inhibited the formation of Ab1-40 fibers, as 
there was no morphological difference between samples analyzed at time zero and after 24 hours 
of aggregation (figure 12, c and d). 
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Figure 12. AFM microscopy of time points of Ab1-40 kinetic either alone or in presence of Hsp60. A. Ab1-40 
50 uM at time zero of the aggregation kinetic, showing absence of aggregates. B. Ab1-40 50 uM after 24 hours 
of aggregation kinetic showing the presence of fibers. C. Ab1-40 50 uM incubated with Hsp60 2 uM at initial 
time of aggregation kinetic showing the presence of small oligomers due to the heptameric and tetradecameric 
structures of Hsp60. D. Ab1-40 50 uM incubated with Hsp60 2 uM after 24 hours of aggregation kinetic 
showing a morphology similar to panel c, suggesting the absence of amyloid aggregates. Scale bars: 1 um, Z-
range 7 nm (a-c) or 9.6 nm (d) [105]. 
 
- Effect of Hsp60 on Ab1-40 aggregation pathway in a cell free model  
I further characterized Hsp60-Ab protein-protein interaction using size-exclusion 
chromatography. Particularly, with this technique I tested the working hypothesis that the effect of 
Hsp60 on Ab1-40 aggregation kinetic was irreversible, thus resulting in a loss of aggregation 
propensity. In detail, size exclusion chromatography (SEC-HPLC) is a both qualitative and 
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quantitative technique that allows to separate components of a sample mixture by size. Particularly, 
the “quality” of the size is given by the retention time (R.T.), expressed in minutes, and the 
“quantity” is given by the area under curve of each specific peak of the chromatogram. Moreover, 
this technique allows to calculate the precise molecular weight of each peak by comparing data 
obtained with the chromatogram of a standard mixture of proteins with known molecular weight. 
Therefore, it was possible analyze the distribution of different aggregates of Ab1-40 that were formed 
after the aggregation kinetic either in absence or upon Hsp60 treatment. Furthermore, to separate 
higher molecular weight oligomers from monomers allowed to employ isolated fractions for further 
analysis, as this technique did not alter the stability of amyloid beta peptide [115]. However, with 
this technique was not possible to observe aggregates with the size of fibers, as the pores of the 
stationary phase did not allow the passage of these aggregates through the column. Therefore, a 
valid approach used to estimate the amount of aggregates formed was to compare the area under 
the curve of the monomeric fractions at two time points of the aggregation kinetic (i.e. 0 and 24 
hours) and to calculate the formation of fibers as the complementary of the monomeric fraction. 
 
 
Figure 13. Comparison between chromatograms after SEC-HPLC injections of Ab1-40 50 µM (green line), 
Hsp60 2 µM (red line) and Ab1-40 50 µM co-incubate with Hsp60 2 µM (black line). 
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In detail, I analyzed and subsequently isolated by SEC-HPLC Ab1-40 fractions either incubated 
or not with Hsp60. As controls, I injected a sample of monomeric Ab1-40 and Hsp60 to estimate the 
retention time of both proteins alone. As summarized in figure 13, the injection of freshly prepared 
Ab1-40 monomers (green line, figure 13), produced a chromatogram characterized by a peak with a 
retention time around 33 minutes. Furthermore, I confirmed that to inject Hsp60 produced peaks 
around minutes 14 and 15.5 minutes (red line, figure 13). As we compared this data to a 
chromatogram of Ab1-40 incubated with Hsp60 under pro-aggregating conditions (black peak, figure 
13), we observed that the peak corresponding to the monomeric fraction of Ab was very similar 
either in quality that in quantity to the untreated control, thus further confirming the anti-
aggregating effect of Hsp60 on Ab1-40. Moreover, I wanted to test the misfolding ability of Ab1-40 
that has been exposed to Hsp60, after SEC-HPLC purification. This test for simplicity has been 
referred as “aggregation assay” (figure 14). Particularly, I prepared two samples: a sample of Ab1-
40 never exposed to Hsp60 and a sample incubated with Hsp60. Both samples are incubated under 
pro-aggregating conditions (24 hours, 37 °C and 200 rpm) prior to the injection into the HPLC 
system. For both samples, fractions around 33 minutes are collected and incubated for 20 hours 
under the same conditions as prior to HPLC injection. Subsequently, I tested with ThT assay in 
both samples (Ab1-40 and Ab1-40 exposed to Hsp60 before SEC-HPLC purification) the presence of 
aggregates, as ThT emission is an indirect measure for fibrillary aggregates.  Figure 14 summarizes 
results obtained from purified fractions of Ab1-40 pre-exposed (blue line) or not (red line) to Hsp60 
for 24 hours and subsequently incubated for further 20 hours under pro-aggregating conditions. 
Data obtained suggests that Ab, once exposed to Hsp60, is not able to aggregate neither after Hsp60 
has been removed. Conversely, chromatographic fractions purified from a sample of Ab1-40 gives 
ThT fluorescence positivity after 20 hours of incubation, due to fiber formation. 
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Figure 14. ThT assay of Ab1-40 samples either treated (blue line) or not (red line) with Hsp60 2 µM, prior to 
HPLC injection and 20 hours of incubation at 37 ° C and 200 rpm (aggregation test) prior to the assay. 
 
- Effect of Hsp60 on Ab1-42 aggregation pathway in a cell free model  
To further validate the anti-aggregating effect of Hsp60, I used Ab1-42 as an alternative model 
of amyloid aggregation. Differently from Ab1-40, the aggregation kinetic of this peptide was much 
faster and, therefore, there was not lag phase observed with the ThT assay, as observed in Ab1-40, 
due to the immediate formation of seeds and aggregates. As summarized in figure 15, there is 
preliminary evidence suggesting an anti-aggregating effect of Hsp60 also on a much more 
aggressive model of aggregation, such as Ab1-42. However, further investigation is needed to 
validate the effect of Hsp60 on Ab1-42 aggregation kinetic. 
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Figure 15. Biophysics analysis of Hsp60 effect on Ab1-42. A. ThT assay of Figure Ab1-42 50 µM (black line) 
suggests that the aggregation is too fast compared to Ab1-40 and therefore peptide concentration is lowered 
until 15 µM (blue line). ThT assay of Ab1-42 treated with Hsp60 suggests that the chaperon inhibits Ab1-42 
aggregation despite the high propensity to aggregate. B. Highlight of first 5 hours of kinetic between Ab1-42 
and Hsp60 shown in figure A to better observe the antiaggregating effect of Hsp60. 
 
- Effect of GroEL on Ab1-42 aggregation pathway in a cell free model  
I further tested if results obtained with human Hsp60 were reproducible with the bacterial 
homolog, GroEL. In detail, as summarized in figure 16, I tested if under the same conditions used 
for human Hsp60, GroEL was also an effective inhibitor of Ab1-40 aggregation kinetic. I addressed 
my working hypothesis using ThT and CD assays. Figure 16A shows the intensity of emission of 
ThT for Ab1-40 either not exposed or exposed to GroEL and data suggested that in these conditions 
(Ab1-40 50 µM and GroEL 2 µM), there was not an inhibition of Ab aggregation. One possible 
explanation of the phenomenon is that the conditions used do not allow an effective inhibition of 
Ab1-40 aggregation. Therefore, I tested a different condition based on isothermal titration 
calorimetry data from our collaborators (unpublished data, not shown). Panel B and C of figure 16 
summarize the results obtained testing Ab1-40 25 µM and GroEL 7 µM (red line), comparted to Ab1-
40 25 µM alone (blue line). Briefly, ThT assay showed the effect of GroEL in increasing the lag 
phase of Ab aggregation, even though the kinetic was not completely blocked. This data was 
consistent with CD data summarized in panel C of figure 16. 
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Figure 16. GroEL effect on Ab1-40 aggregation kinetic characterized by ThT assay and CD analysis. A. ThT 
assay of Ab1-40 50 µM exposed to GroEL 2 µM (red line) compared to Ab1-40 50 µM untreated (blue line). B. 
ThT assay of Ab1-40 25 µM exposed to GroEL 7 µM (red line) compared to Ab1-40 25 µM untreated (blue line). 
C. Summary of CD spectra measured at time points of the aggregation kinetic of Ab1-40 exposed to GroEL: 0 
(black line; 2 hours (green line); 18 hours (magenta line). Data was compared to Ab1-40 kinetic: 0 (black dotted 
line); 2 hours (green dotted line); 4 hours (blue dotted line). 
 
2. Characterization of the protective effect of Hsp60 against Ab toxicity in vitro 
 
- Co-expression of APP and Hsp60 in vitro: 7PA2/H60 cell line design and validation 
Results discussed in the previous section suggest a direct inhibitory effect of Hsp60 on Ab 
aggregation. Therefore, I wanted to test the working hypothesis that Hsp60 has a direct effect on 
Ab cascade using a more complex model. Therefore, I used as a model a cell line overexpressing 
the Swedish variant of APP (7PA2 cells) and that is known to release human Ab oligomers in the 
culture medium, that are known to be toxic if injected in vivo [116,117]. Therefore, this has been 
used as a good model to test the effect of Hsp60 on Ab oligomers in vitro. Figure 17 summarizes 
the experimental design for the study of Hsp60-Ab protein-protein interaction in vitro. Briefly, I 
transfected 7PA2 cell line using a pCMV6 plasmid either empty, as a control, or encoding for 
human Hsp60 protein 24 hours after cells were seeded on a multiwall plate at desired confluency. 
Optimal transfection conditions were tested using either different volumes of lipofectamine 2000 
(7, 9, 12 µL) or different plasmid concentrations (1,3,5,7 µg). Condition tested are summarized in 
table 2.   
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Figure 17. Experimental design for in vitro overexpression of Hsp60 on 7PA2 cell line that overexpresses APP. 
After transfection (I), cell will be selected with hygromycin (II) and validated by WB and IIC (III). Subsequently, 
sub-cellular fractionation and analysis of Hsp60-Ab co-expression in subcellular compartments will be also 
tested (IV). 
 
Despite the conditions chosen (different volumes of lipofectamine or different quantities of 
cDNA), all transfections were blocked after 5 hours with DMEM 10% FBS and cells kept for 24 
hours without antibiotics to allow cells to recover. 
 
 Table 2. Summary of condition tested to optimize cell transfection. 
 
 
Transfection efficiency was verified using both western blotting (WB, figures 19, 20) and 
immunocytochemistry (ICC, figures 21-23). For both experimental approaches, detection and 
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quantification of recombinant Hsp60 protein was verified by a specific antibody for the c-terminus 
tag (DDK antibody) and by a specific antibody for detecting total Hsp60 levels. Some of the 
conditions that have been tested on both CHO and 7PA2 cell lines are summarized in a 
representative immunocytochemistry presented in figure 18. Particularly, in blue are stained nuclei 
with DAPI and in green is strained the recombinant protein that has been overexpressed after 
plasmid transfection, using DDK antibody. Based on these preliminary results, 3 µg cDNA and 7 
µl Lipofectamine 2000 were used to create the cellular model which co-expressed APP and Hsp60, 
that will be referred in the following text as “7PA2/H60” cell line. 
 
 
Figure 18. Immunocytochemistry (ICC) of CHO and 7PA2 with pCMV6 plasmid encoding from recombinant 
Hsp60. A-E. CHO cell line transfected with increasing concentrations of pCMV6-Hsp60 plasmid (1,3,5,7 µg). 
F-J. 7PA2 cell line transfected with increasing concentrations of pCMV6-Hsp60 plasmid (1,3,5,7 µg). 
Antibodies: DAPI, blue = nuclei; DDK, green= recombinant Hsp60. 
 
To select a transient cell line that co-expresses both APP and Hsp60 proteins, I characterized 
the minimum concentration of antibiotics that was toxic for cells that did not have the plasmid, as 
both plasmids that have been used to create the cell lines encoded for specific antibiotic resistance. 
Particularly, the plasmid responsible for APP expression in 7PA2 cell line expressed also the 
resistance for neomycin (or G418 antibody), while the plasmid encoding for Hsp60 expressed also 
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hygromycin resistance. Based on kill curves obtained with CHO and 7PA2 cells exposed for 1 week 
to serial concentrations of antibiotics (data not shown), 7PA2/H60 cell line was obtained using 
G418/hygromycin B 0.6 mg/0.6mg in DMEM, 10 % FBS, 1% p/s. Positive transfection was also 
tested with WB blotting technique after one week and one month of transfection, as summarized in 
figure 19. Particularly, I verified the overexpression of APP by WB using 6E10 antibody, which 
stained for APP/Ab in 7PA2 and 7PA2/H60 cell lines, compared to naïve CHO cells. Moreover, I 
confirmed the overexpression of recombinant Hsp60 only in 7PA2/H60 cell line using a specific 
antibody anti-tag expressed in the recombinant protein (DDK) and I further validated the co-
localization of the signal obtained with DDK and Hsp60, thus confirming that the overexpressing 
recombinant is Hsp60 (Figure 19, A).  
 
 
Figure 19. Western blotting (WB) validation of 7PA2/H60 cell line. A. representative WB of total lysates of 
CHO, 7PA2 and 7PA2/H60 confirming that all cell lines are positive to total Hsp60 antibody, that only 
7PA2/H60 is positive to DDK antibody for recombinant Hsp60 and that only 7PA2 and 7PA2/H60 are positive 
to 6E10 antibody (APP/Ab). B. representative WB of total lysates of CHO, 7PA2 and 7PA2/H60 after 1 week 
and after 1 month of transfection (7PA2/H60 Ly II) using 6E10 (APP/Ab), DDK and Hsp60 antibodies confirms 
the validation of 7PA2/H60 cell line. C. Quantification of WB bands presented in B. 
 
Subsequently, I confirmed the expression of all proteins of interest (APP/Ab, total and 
recombinant Hsp60) also after a long exposure (1 month, figure 19 line “7PA2/H60 Ly II”) to toxic 
concentrations of selection antibody (figure 19, B). I further quantified the levels of DDK, Hsp60, 
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APP (considering the lower band in the 130 KDa range) and Ab ( 4 KDa band), either after one 
week (“7PA2/H60 I” line, panel B and C of figure 19) or after one month (7PA2/H60 II line, panel 
B and C of figure 19) of transfection, using ImageJ, as summarized in figure 19C. Overall, data 
suggests a successful overexpression of Hsp60 in 7PA2 cells already overexpressing APP protein.  
I further validated the overexpression of APP and Hsp60 in 7PA2/H60 cell line comparing the 
transfection with cells transfected with an empty plasmid, as summarized in figure 20. Particularly, 
panel A is a representative western blotting of total cell lysates from CHO, 7PA2, 7PA2 transfected 
with empty plasmid and 7PA2/H60 cell lines to test the expression of APP, total Hsp60 and 
recombinant Hsp60. The quantification of the bands for Hsp60, DDK and APP proteins normalized 
to b-actin is summarized in panel B. This data validated the co-expression of APP/Ab and Hsp60 
in the novel cellular model referred as 7PA2/H60 cell line. 
 
 
Figure 20. Western blotting (WB) validation of 7PA2/H60 cell line. A. representative WB of CHO, 7PA2, 7PA2 
transfected with empty pCMV6 plasmid and 7PA2/H60, validating that 7PA2/H60 cell line co-expresses APP 
and recombinant Hsp60. B. quantification of blot presented in panel A, using ImageJ. 
 
In parallel experiments, I characterized 7PA2/H60 cell line using immunocytochemistry (ICC). 
Particularly, I validated APP/Ab expression of in 7PA2 and 7PA2/H60 cell lines, compared to CHO 
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as a control, using 6E10 antibody for APP/Ab detection. Furthermore, I validated the expression of 
total Hsp60 in all cell lines used, CHO, 7PA2 and 2PA2/H60 lines, as Hsp60 is a ubiquitous protein. 
Finally, I confirmed the expression of recombinant Hsp60 in 7PA2/H60 cell line using DDK 
antibody and confirmed the co-localization with Hsp60 antibody. Representative ICC data is 
summarized in figure 21, 22 and 23. 
 
 
Figure 21. ICC validation of 7PA2/H60 cell line. Data confirms that Hsp60 is expressed in all cell lines as this 
protein is ubiquitous and that the expression of APP is only in 7PA2 and 7PA2/H60 cell lines. DAPI, blue= 
nuclei; Hsp60rb, green= total Hsp60; 6E10ms, red= APP/Ab.  
 
Particularly, figure 21 is a representative immunocytochemistry of CHO, 7PA2 and 7PA2/H60 
cell line stained with DAPI for nuclei detection (blue channel), Hsp60 antibody for total Hsp60 
detection (green channel) and 6E10 antibody (red channel) for APP/Ab detection, showing that 
only 7PA2 and 7PA2/H60 cell lines were positive for 6E10 antibody and therefore expressed APP 
protein. Figure 22 is a representative immunocytochemistry of CHO, 7PA2 and 7PA2/H60 cell line 
  52 
stained with DAPI for nuclei detection (blue channel), Hsp60 antibody for total Hsp60 detection 
(green channel) and DDK antibody (red channel) for recombinant Hsp60 detection, showing that 
only 7PA2/H60 cell line was positive for DDK antibody and therefore expressed recombinant 
Hsp60 protein. 
 
 
Figure 22. ICC validation of 7PA2/H60 cell line. Data confirms the expression of Hsp60 in all cell lines and 
only in 7PA2/60 the expression of recombinant Hsp60 as confirmed by the co-localization of total Hsp60 and 
DDK antibodies. DAPI, blue= nuclei; Hsp60rb, green= total Hsp60; DDKms, red= recombinant Hsp60. 
 
Figure 23 is a representative immunocytochemistry of CHO, 7PA2 and 7PA2/H60 cell line 
stained with DAPI for nuclei detection (blue channel), DDK antibody for recombinant Hsp60 
detection (green channel) and 6E10 antibody for APP/Ab  detection (red channel), showing that 
only 7PA2/H60 cell line co-expressed both APP and recombinant Hsp60 proteins. 
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Figure 23. ICC validation of 7PA2/H60 cell line. Data confirms the expression of both APP and recombinant 
Hsp60 in 7PA2/H60 cell lines. DAPI, blue= nuclei; DDKrb, green= recombinant Hsp60; 6E10ms, red= 
APP/Ab. 
 
- Investigating the co-expression of APP and Hsp60 in sub cellular compartments 
The novel cellular model that co-expressed both APP and Hsp60 proteins allowed to investigate 
the effect of Hsp60 on Ab cascade in vitro. Particularly, I investigated the working hypothesis that 
Hsp60 as an effect on APP and Ab production in different sub-cellular compartments: whole cell, 
mitochondria and extracellular compartment. The rationale of this investigation was based on the 
known toxic localization of Ab oligomers into the mitochondria and the known protective action 
of Hsp60 in the mitochondria [118,119]. Moreover, the following experiments aimed to support the 
beneficial effect on enhancing the chaperone machinery as a potential approach for future therapies 
for Alzheimer’s disease. As the goal is to investigate the functional interaction between Ab and 
Hsp60 in sub-cellular compartments, I first validated the protocols for mitochondria isolation and 
extracellular compartment purification. In detail, mitochondria isolation has been done using 
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Qproteome mitochondria isolation kit (Qiagen), based on the manufacturer protocol. The purity of 
isolated mitochondria has been validated by western blotting in all three cells lines of interest (CHO, 
7PA2 and 7PA2/H60 cell lines) and the protein validation is summarized in figure 24 with a 
representative western blotting. Particularly, the comparison of total cell lysates with cytoplasmic 
and mitochondria fractions allowed to observe an enrichment in SOD2 positive band in the 
mitochondria fraction, as SOD2 is a specific enzyme expressed in mitochondria. Both Hsp60 and 
SOD2 bands were normalized to b-actin, used as loading control. 
 
 
Figure 24. WB validation of mitochondria and cytosolic fractions of CHO, 7PA2 and 7PA2/H60 using 
Qproteome mitochondria isolation kit. Data confirms that Hsp60 and SOD2 are compartmentalized in the 
mitochondria of all cell lines. 
 
Moreover, as it is known from literature that 7PA2 cells secrete Ab into the media and that once 
released [108, 117, 120], it aggregates into toxic oligomers, I optimized the protocol from media 
concentration from CHO, 7PA2 and 7PA2/H60 cell line to test the working hypothesis that Hsp60 
has a direct influence on Ab release in the media. Figure 25 summarizes the experimental design 
applied for media isolation. 
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Figure 25. Experimental design of extracellular fractions isolated from CHO, 7PA2 and 7PA2/H60 cell lines. 
1. Cell are first seeded in a Petri dish in regular media and after 3 hours, all media is replaced with serum free 
and antibiotics free DMEM and cells left in the incubator for 20 hours. 2. After 20 hours, conditioned media 
(CM) is collected and concentrated up to 20 times. 3. All concentrated fractions are analyzed with WB and 
ELISA. 
 
Briefly, I first seeded CHO, 7PA2 and 7PA2/H60 cell lines in Petri dishes at about 90% 
confluency and allowed cells to attach for 3 hours in regular media. After 3 hours, I washed and 
left all cells in serum-free, antibiotics-free DMEM media. After 20 hours in the incubator, I 
removed the media and I either concentrated media up to 20 times for analysis of Ab levels via WB 
and ELISA or either used for toxicity assay (described in the following chapter).  
The characterization using western blotting of conditioned media (CM) isolated and 
concentrated from CHO, 7PA2 and 7PA2/H60 cell lines is summarized in figure 26. Particularly, I 
tested the levels of APP/Ab using the specific anti amyloid antibody 6E10. As expected, only 7PA2 
and 7PA2/H60 cells are positive to 6E10 antibody either in lysates and CM. 
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Figure 26. WB validation of conditioned media (CM) fractions of CHO, 7PA2 and 7PA2/H60 cell lines, 
compared to total lysates. 6E10 antibody confirms the positivity to APP/Ab proteins only in 7PA2 and 
7PA2/H60 media. Hsp60 antibody confirms the presence of Hsp60 protein only in total lysate fractions.	
 
After I validated all protocols for mitochondria and extracellular environments, I investigated 
the effect of Hsp60 overexpression on APP/Ab in whole cells, cytoplasm, mitochondria and 
extracellular compartments. A representative western blotting of whole cell lysates of CHO, 7PA2 
and 7PA2/H60 cell lines using 6E10 antibody for APP/Ab fragments, DDK for recombinant Hsp60 
and Hsp60 for total Hsp60 is presented in figure 27 A. Quantification of the bands is summarized 
in panel B of figure 27. 
 
 
Figure 27. Co-expression of Hsp60 and APP/Ab proteins in whole cell compartment. A. representative WB of 
total cell lysates of CHO, 7PA2 and 7PA2/H60 cell lines confirms the co-expression of Hsp60 and APP and 
suggests a reduction in APP expression as Hsp60 is overexpressed. B. Quantification of WB using ImageJ.  
 
Overall, data suggested that the overexpression of Hsp60 reduced APP levels in total cell lysates 
that, however, was not significant after further investigations (data not shown). 
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Furthermore, I tested levels of total Hsp60, recombinant Hsp60 and APP/Ab levels in 
mitochondria, cytoplasm and extracellular environments (referred as conditioned media or CM). 
As summarized in figure 28, there was not a significant reduction in APP levels in 7PA2/H60 cell 
line compared to 7PA2 cell line. This data suggested that to overexpress Hsp60 might not have a 
direct effect on APP protein, despite it was observed a slight reduction of APP levels in 7PA2/H60 
cell line.   
 
 
Figure 28. Co-expression of Hsp60 and APP/Ab proteins in cytoplasm, mitochondria and extracellular 
compartment. A. representative WB of the Comparison between total lysates, mitochondria and media (CM) 
compartments of CHO, 7PA2 and 7PA2/H60 cell lines suggests that Hsp60 overexpression reduces the amount 
of APP in all compartments investigated. B., C. Quantification of WB bands presented in panel A using ImageJ. 
 
However, as Ab levels in both 7PA2 and 7PA2/H60 cell lines were in the order of picograms, 
it was challenging to detect the 4.5 KDa band of Ab peptide via WD, especially in the conditioned 
media. Indeed, ELISA has been used as more sensitive technique allowing to detect low 
concentrations of Ab peptide. 
  58 
 
Figure 29. Aβ1-42 ELISA of conditioned medium concentrated from CHO, 7PA2 and 7PA2/H60 cell lines 
suggests that Hsp60 overexpression reduces the amount of Aβ secreted in the medium 
 
Figure 29 shows the levels of Ab1-42 detected by ELISA in media concentrated from CHO, 
7PA2 and 7PA2/H60 cell lines. Interestingly, Hsp60 overexpression reduced Ab secreted levels in 
7PA2/H60 media compared to 7PA2, as confirmed by ELISA assay. Overall, data suggested that 
to overexpress Hsp60 has an effect of a downstream cascade of APP, thus resulting in a reduction 
in Ab levels in the extracellular compartment. 
 
3. To determine Hsp60-dependent functional inhibition of downstream 
amyloid beta toxicity 
 
As soon as Ab is released by APP processing, toxic oligomers are formed and they are known 
to be responsible to bind synapses, cause neurotoxicity, and inhibit the functional process of long 
term potentiation, the mechanism involved in memory formation [53, 117]. Therefore, in this study, 
I tested the hypothesis that Hsp60 inhibits Ab-driven neurotoxicity in vitro. Particularly, I 
investigated the effect of Hsp60 on naturally secreted oligomers, formed in vitro by 7PA2/H60 cell 
line (APP-Hsp60 co-expressing cell line) and I compared the effect to 7PA2, a cell line known to 
release toxic oligomers in the media [117]. The change in cytotoxicity was determined using LDH 
assay, as described in material and methods. 
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Figure 30. Effect of Hsp60 on Aβ cytotoxicity. A. LDH assay of SHSY5Y after 24 hours’ treatment, with two 
different doses of CHO and 7PA2 CM, confirms the increased toxicity of 7PA2 media due to the release of 
toxic Aβ oligomers. B. LDH of SH-SY5Y cells exposed 24 hours to conditioned medium extracted from 7PA2 
and 7PA2/H60 cell lines (7PA2-CM or 7PA2/H60-CM) suggests that Hsp60 overexpression reduces the 
amount of Aβ secreted in the medium and cytotoxicity.	
 
The optimization of SH-SY5Y treatment of two different dilutions of conditioned media 
produced by naïve CHO and 7PA2 cell lines is summarized in Figure 30 A. As expected, 7PA2 cell 
line is toxic for neuroblastoma cells, because of the release in the media of cytotoxic oligomers. As 
shown in figure 30B, I compared the toxicity of 7PA2 media to 7PA2/H60 media and data suggested 
that 7PA2/H60 media is less toxic compared to 7PA2 media, thus suggesting an effect of Hsp60 on 
Ab oligomer release or a reduction of toxic species released in the media. However, this approach 
cannot exclude that the phenomenon observed using 7PA2/H60 cell media was only related to a 
reduction of toxic Ab, due to a reduced release, and therefore to a false negative due to a dilution 
effect. Therefore, I tested the effect of Hsp60 on preformed oligomers, as it has been extensively 
discussed that Ab toxicity relies on its oligomeric conformation. To test the hypothesis that Hsp60 
is protective against oligomer-induced cytotoxicity, I prepared Ab oligomers using a protocol 
optimized in our laboratory [53], and I treated an aliquot with two different concentrations of Hsp60 
in aseptic conditions. Moreover, to eliminate the activity of Hsp60, prior to each cell treatments, I 
heat-inactivated the chaperone by boiling the sample and I confirmed by western blotting the quality 
of oligomers using 4G8 antibody. Particularly, figure 31 shows a representative WB to confirm the 
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levels of Ab oligomers in all conditions tested: oligomers freshly prepared, boiled, incubated 1 hour 
at 37 °C, or 3 hours, or incubated 1 hour and boiled. Furthermore, I tested the quality of oligomers 
also after exposure to Hsp60. 
 
 
Figure 31. WB characterization of preformed Ab oligomers exposed to different conditions. Samples exposed 
to Hsp60 were incubated with Hsp60 for 1 hour at 37 °C and bold for 1 minute to heat inactivate Hsp60. The 
procedure did not alter the quality of preformed oligomers. 
 
Moreover, I tested the optimal concentration of Ab oligomers that was toxic for SH-SY5Y and, 
as described in figure 32, Ab oligomers were toxic either at 5 and 10 µM. Indeed, I decided to use 
Ab 5 µM for testing changes in cytotoxicity upon Hsp60 treatment. As summarized in figure 33, I 
tested the effect of two different concentrations of Hsp60 on Ab-induced toxicity. Particularly, I 
exposed Ab oligomers to Hsp60 1 or 2 µM and I tested the toxicity of Hsp60 at the same condition 
as control. Sample were diluted 10 times and, therefore, in the graph are reported final 
concentrations administered to cells. 
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Figure 32. LDH assay of SH-SY5Y cells exposed to an increasing concentration of Aβ oligomers allows to 
select the optimal concentration of oligomers that are cytotoxic for neuroblastoma cells. 
 
Data suggested that 200 nM of Hsp60 dramatically reduces Ab-induced cytotoxicity, even 
though, at this concentration Hsp60 alone seems to be cytotoxic. A possible explanation of this 
phenomenon lays on the known role of Hsp60 in pro-death pathways [94] and therefore, if cannot 
be excluded that at lower concentrations Hsp60 is engaged in pro-apoptotic pathways. 
Consequently, other concentrations might be investigated to find an optimal concentration of Hsp60 
that is well tolerated also in absence of Ab oligomers. 
 
 
Figure 33. LDH assay of SH-SY5Y cells exposed to different treatments (Aβ, Aβ + Hsp60 or Hsp60) suggests 
that Hsp60 can prevent Aβ toxicity in certain conditions. 
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4. To determine Ab and Hsp60 co-expression in post mortem tissues 
 
Based on previous studies suggesting a relationship between the toxic accumulation of Ab and 
impairment of chaperone levels in post mortem human tissues [121, 122], I characterized the co-
expression of both proteins in total homogenates, synaptosomes and mitochondria by western 
blotting. Data summarized in figure 34 shows a representative WB in the left panel of total 
homogenates, mitochondria or synaptosomes isolated from either AD or age-matched controls, in 
the right panel the quantification of Hsp60 levels obtained by n=3 samples for each condition 
considered. 
 
 
Figure 34. Levels of Hsp60 by WB in AD individuals compared to healthy controls suggest a trend of reduction 
in AD patients. Hsp60 is particularly reduced in mitochondria compartment when comparing total 
homogenates, synaptosomes and mitochondria (n=3). 
 
Results obtained from Hsp60 quantification suggested a trend of reduction on Hsp60 levels in 
AD compared to controls. However, a larger number of sample will be required to test the working 
hypothesis is Hsp60 levels correlate with Ab levels. Furthermore, a possible effect of the post-
mortem interval on Hsp60 levels should also be taken into consideration. 
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Discussions 
AD is the 6th leading cause of death and this disease is going to increase its costs due to the 
absence of therapies [27]. One of the earliest hallmarks of AD pathogenesis is Ab formation and 
aggregation into toxic oligomers that, together with the misfolding of other proteins, the impairment 
of the protein quality control machinery causes the disease. As Ab neurotoxicity is one of the 
earliest events of the disease, this project aims to characterize a possible mechanism able to inhibit 
this toxicity. Based on what is the current knowledge on Ab misfolding and aggregation pathway, 
there are several strategies that can be used to inhibit this process: to increase the clearance of Ab 
oligomers and therefore to potentiate the removal of toxic species; to target toxic oligomers and 
readdress the aggregation cascade toward less toxic conformations; to target Ab monomers, as soon 
as they are released, and directly inhibit the toxic “on-pathway” toward an trigger an alternative 
and less toxic “off-pathway”.  
Increasing research suggests that chaperones are protective machines that can counterbalance 
the toxic effect of other proteins [123-125]. Therefore, in my study I proposed to investigate the 
role of Hsp60 in interacting with Ab peptide and I tested the potential protective effect against Ab-
induced neurotoxicity as a potential therapeutic strategy relevant to AD. In fact, to propose this 
chaperone as a backbone for any active therapy, it is crucial to define the mechanism of action, 
which so far is poorly understood. 
The well characterized native properties of chaperonins Hsp60 in assisting the refolding of 
misfolded proteins, gave the rationale to propose a direct interaction between the two proteins. 
Therefore, I characterized the change in Ab aggregation in presence of Hsp60 using Thioflavin T 
assay, circular dichroism spectroscopy, atomic force microscopy and size exclusion 
chromatography. I first investigated the effect of Hsp60 on Ab aggregation by testing the protein-
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protein interaction without the complexity of a cellular environment. Particularly, I confirmed that 
the mitochondrial form of human Hsp60 successfully inhibits the aggregation of either Ab1-40 and 
Ab1-42 peptides, using both Thioflavin T and circular dichroism analysis. Moreover, my data 
suggests that the machinery is acting also in absence of ATP, therefore I speculate that possibly 
Hsp60 offers a particularly hydrophobic surface that forces the aggregation of Ab toward an “off-
pathway” cascade, as after Hsp60 removal, the exposed amyloid peptide is not able to seed a new 
aggregation toward fiber formation a phenomenon already observed by others with fatty acids 
[126]. Moreover, the effect of Hsp60 in readdressing Ab into an “off-pathway” seems irreversible, 
as purified Ab exposed to Hsp60 loses the ability to aggregate even though exposed to pro-
aggregating conditions.  Moreover, data obtained with bacterial GroEL proposes that the possible 
mechanism of direct inhibition observed with the human homolog Hsp60 could be linked to a more 
evolved ability to operates also when the co-chaperone and ATP are not available, thus making this 
chaperone more evolved than the bacterial homologue GroEL.  
As Hsp60 in a cell free model blocks Ab aggregation and readdressed the amyloid pathway 
towards intermediates that have lost the ability to aggregate, I further investigated the effect of 
Hsp60 on Ab production, compartmentalization and release by creating a novel cellular model that 
overexpresses both human amyloid precursor protein (APP) and human Hsp60 (referred as 
7PA2/H60 cell line). This model supported the hypothesis that to overexpress Hsp60 protects 
against amyloid toxicity by reducing Ab production as confirmed by ELISA of the extracellular 
media (conditioned media). Subsequently, I tested the effect of Hsp60 in inhibiting Ab-driven 
cytotoxicity using SH-SY5Y cells as a neuronal model in vitro. Particularly, I tested the effect of 
Hsp60 on naturally secreted oligomers and preformed oligomers and tested the change in 
cytotoxicity compared to untreated oligomers. Overall, data suggests the protective action of Hsp60 
against Ab-driven cytotoxicity. Overall, data obtained can be summarized using the working model 
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summarized in figure 35. Briefly, Hsp60 targets either misfolded monomers or oligomers of Ab, 
thus resulting in an irreversible inhibition of aggregation kinetic and the inhibition of Ab-induce 
cytotoxicity as confirmed by data on neuroblastoma cell lines. Therefore, Hsp60 could be an 
attractive target for future therapies for Alzheimer’s disease. Moreover, preliminary data obtained 
from post mortem tissues of AD brains, compared to healthy brains, suggested an impartment of 
Hsp60 levels that could be the outcome of an increased demand to counterbalance the aberrant 
production of toxic species responsible for AD pathogenesis.  
 
 
Figure 35. Working model of the effect of Hsp60 on amyloid beta cascade and downstream toxicity. 
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Conclusions 
Chaperones are an important component of the cellular protein quality control machinery. 
Increasing evidence suggests a direct interaction between chaperones and misfolded proteins 
characterizing several neurodegenerative diseases and proposes chaperones as protective guardians 
of cellular homeostasis [127, 128]. Alzheimer’s disease is one example of neurodegenerative 
disorders, and often it has been defined by others as “protein misfolding pathology” [129, 130], as 
one of the hallmarks of the disease is Ab formation and aggregation into neurotoxic forms leading 
to neurodegeneration. The aim of my project is to investigate the protective action of the 
mitochondrial chaperone Hsp60 against Ab toxicity and proposes a novel approach against one of 
the causes of AD. Hsp60, as part of the protein quality control machinery, is known to protect the 
cell against stressors that alter cellular homeostasis. Moreover, there is evidence suggesting that 
Hsp60 might be involved in an aberrant circuitry triggered by amyloid misfolding and neurotoxicity 
[100]. Therefore, upregulating Hsp60, could contribute to prevent neurons to degenerate due to 
amyloid toxicity. Particularly, results in a cell free system highly suggest the inhibitory effect of 
Hsp60 on Ab aggregation via an irreversible change in conformation of Ab peptide. Moreover, in 
vitro results are highly suggestive that Hsp60 influences Ab release, possibly due to a direct effect 
on APP processing or on sub-cellular localization thus resulting in a reduction of Ab release in the 
extracellular compartment. Further investigations to better characterize the protective effect of 
Hsp60 in vitro might be needed to further confirm biochemistry of the process. 
To test the effect of Hsp60 on Ab cytotoxicity in vitro, suggests that Hsp60 significantly reduces 
the toxicity of both naturally secreted or preformed Ab oligomers. Overall, the project contributes 
to characterize a poorly investigated mechanism of protection of the mitochondrial chaperonin 
  67 
Hsp60 against Ab toxicity, one of the main hallmarks of Alzheimer’s disease and proposes Hsp60 
as a potential key factor to consider for novel therapies. 
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Future directions 
 
Increasing evidence suggests that Ab toxicity is due to specific oligomeric conformations (or 
“strains”) acquired during Ab aggregation kinetic [131, 132]. Therefore, any approach able to 
interfere with the formation of toxic oligomeric strains of Ab is a successful strategy for future 
disease-modifying therapies. Using a cell free system, I showed that Hsp60 inhibits Ab aggregation. 
Therefore, this data proposes Hsp60 as an effective inhibitor of Ab aggregation. However, this study 
did not clarify what is the effect of Hsp60 on oligomeric strains of Ab, which are known to have 
different neurotoxicity and to be the most relevant species for the onset of AD. Therefore, a future 
experiment will aim to test the working hypothesis that Hsp60 is responsible for inducing a change 
in Ab oligomerization by changing its oligomeric strain toward less toxic species. To use specific 
antibodies against oligomeric conformation will provide evidence of the effect of Hsp60 on toxic 
Ab strains. 
To further validate the protective role of Hsp60 against amyloid-b toxicity, the protective effect 
of Hsp60 on Ab neurotoxicity should be investigated also in vivo. In fact, to propose Hsp60 as a 
potential future therapy relevant to AD, should be confirmed if Hsp60 reverts some of the known 
phenotypes caused by Ab toxicity: inhibition of the long-term potentiation and alteration of 
memory. In fact, this experiments will contribute to improve the understanding of the role of Hsp60 
in AD and will provide a strong support for future therapeutics for AD. 
Another interesting direction would be to investigate if there is a relationship between Hsp60 
levels and the main risk factor responsible for the onset of sporadic AD, Apo Ee4, as the role in the 
onset of sporadic AD is poorly understood. An intriguing hypothesis lays on the recent discovery 
of a link between Apo E and clusterin [133], an extracellular chaperone known to be involved in 
cell survival and stress response and whose mechanism of action seems to be antagonized by a 
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direct binding to Hsp60 [134]. Interestingly, increased levels of clusterin have been associated with 
AD pathology and particularly with levels of APOE and increased secreted levels of tau and Ab. 
Therefore, it would be interesting to test the hypothesis that the genetic variant Apo Ee4 has a role 
in influencing the chaperone machinery leading to a pathologic accumulation of pro-amyloid 
peptides, causing AD onset. The rationale that could support this hypothesis is the known 
interaction between ApoE, clusterin and Hsp60 [133,134]. A possible experimental approach could 
be to determine Hsp60 levels in transgenic mice expressing the human ApoE3, ApoE4 and ApoE2 
variants and investigate if changes in Hsp60 levels might be indirectly influenced by increased 
levels in clusterin.  
Another interesting aspect that might deserve further investigation concerns the observation that 
AD progression is linked to an impairment of inhibitory GABA neurons because of an accumulation 
of amyloid plaques, a phenomenon referred as “disinhibition” [135]. As the process seems to 
selectively involve a specifically GABA interneurons, it would be interesting to investigate both in 
vivo or ex vivo on animal models the hypothesis that this phenomenon of GABA-dependent 
disinhibition, leading to a “synaptic failure” characteristic of AD [136], could be influenced by an 
impairment of Hsp60 levels. To support this hypothesis will require functional studies using 
pharmacologic and electrophysiology approaches that will allow to test if to increase Hsp60 levels 
could compensate the impairment of GABAergic neurotransmission leading to aberrant firing and 
synaptic dysfunction.  
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AD = Alzheimer’s disease 
Ab = amyloid beta 
APP = amyloid precursor protein 
CSF = cerebral spinal fluid 
NDAN = Non-Demented with Alzheimer’s Neuropathology 
fAD = familiar Alzheimer’s disease 
sAD = sporadic Alzheimer’s disease 
BACE1 = beta-secretase 1 
MW = molecular weight 
IDRs = intrinsically disordered regions 
Hsp6 0 = Heat shock protein 
AFM = Atomic force microscopy 
HFIP = Hexafluoro-2-propanol 
ThT = Thioflavin T 
CD = Circular Dichroism 
HPLC= High performance liquid chromatography 
SEC= Size exclusion chromatography 
CHO = Chinese Hamster Ovary 
7PA2 = CHO overexpressing APPswe protein  
7PA2/H60= 7PA2 overexpressing Hsp60 
DMEM = Dulbecco’s modified Eagle Medium 
FBS = Fetal bovine serum 
CM= Conditioned Medium 
WB = Western blotting 
PBS = Phosphate buffer saline 
ICC = Immunocytochemistry 
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